Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMG-007 in moderate-to-severe atopic dermatitis
NCT05984784Phase 2Terminated
- Start
- Aug 2023
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of IMG-007 in atopic dermatitis (AD). Started Aug 2023; status: terminated.
02
Drugs
IMG-007
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05984784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05984784.